Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 22Terminated 5Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × MART-1 Antigen × Clear all
NCT00010309 2014-01-06

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Dermatologic

Melanoma

NCT00037037 2013-12-18

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1 Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡